EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ligand Pharmaceuticals EBITDA Margin % Related Terms
Ligand Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ligand Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LGDN vs DFTX, CGON, XENE: EBITDA Margin % Comparison
For the Biotechnology subindustry, Ligand Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ligand Pharmaceuticals EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ligand Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ligand Pharmaceuticals (FRA:LGDN) has a EBITDA Margin % of -27.64% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ligand Pharmaceuticals and its competitors. Over the past decade, Ligand Pharmaceuticals' EBITDA Margin % has ranged from 24.41 to 728.38. According to the industry distribution chart, Ligand Pharmaceuticals ranks #26 out of 942 companies in the Biotechnology industry, placing it in the top 2.8%.
Is Ligand Pharmaceuticals' EBITDA Margin % too high?
Ligand Pharmaceuticals' current EBITDA Margin % is -27.64%. Over the past 10 years, this metric has ranged from a low of 24.41 to a high of 728.38. Based on the distribution chart, Ligand Pharmaceuticals ranks #26 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ligand Pharmaceuticals has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' EBITDA Margin % compare to DFTX and CGON?
According to the Biotechnology industry distribution chart, Ligand Pharmaceuticals ranks #26 out of 942 companies for EBITDA Margin %. This places Ligand Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. Historically, Ligand Pharmaceuticals' own EBITDA Margin % has ranged from 24.41 to 728.38 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ligand Pharmaceuticals and its competitors. Ligand Pharmaceuticals's current EBITDA Margin % is -27.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €147.69, compared to a current price of €254.00 — trading 72% above its estimated fair value. The current EBITDA Margin % is -27.64%. Ligand Pharmaceuticals' overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current EBITDA Margin % is -27.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?
Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued.
The current stock price of €254.00 is trading 72% above its estimated GF Value™ of €147.69.
GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:LGDN:
EBITDA Margin %: -27.64%
GF Value™: €147.69 vs. price of €254.00 (72% above fair value)
No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
76GF Score
Get the complete analysis for FRA:LGDN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LGDN has been successfully added to your 
